Evidence map›Paper›PMID 41216205›Full record

ArticleAdvances in radiation oncology2025

Particle Therapy in the Multimodal Treatment for Locally Advanced Malignancies of the Nasal Cavity and Paranasal Sinus-Single Institute Experience.

Fatima Frosan Sheikhzadeh, Gertrud Schmich, Niklas Recknagel, Edgar Smalec, Tasneim Abdelrahman Mohamed, Vicky Soborun, Kerem Tuna Tas, Philipp Lishewski, Klemens Zink, Khaled Elsayad and 6 more

Abstract read
In one paragraph

Article in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Fatima Frosan SheikhzadehDepartment of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany.
Gertrud SchmichDepartment of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany.
Niklas RecknagelDepartment of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany.
Edgar SmalecDepartment of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany.
Tasneim Abdelrahman MohamedDepartment of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany.
Vicky SoborunDepartment of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany.
Kerem Tuna TasDepartment of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany.
Philipp LishewskiDepartment of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany.
Klemens ZinkDepartment of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany.
Khaled ElsayadDepartment of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany.
Fabian EberleDepartment of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany.
Hilke VorwerkDepartment of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany.
Thomas HeldDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Boris A StuckUniversity Cancer Center Frankfurt - Marburg, Marburg, Germany.
Sebastian AdebergDepartment of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany.
Ahmed GawishDepartment of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Particle therapy with protons or carbon ions is a promising method for treating locally advanced nasal cavity and paranasal sinus carcinomas (NPSC). This study evaluates the clinical outcomes and toxicities of patients treated with carbon ion radiation therapy with a boost (CIRT-B) at our institution. Methods and Materials: Patients with NPSC who received combined treatment with CIRT-B and intensity modulated radiation therapy were considered. Local control (LC) and survival rates were estimated using Kaplan-Meier survival analysis and proportional hazards models. Results: Between 2016 and 2023, a total of 66 patients were included in the analysis. Of these, 53 patients (80%) received primary radiation therapy as their first-line treatment, while 13 patients (20%) underwent salvage reirradiation for recurrent disease. The median total dose administered in the upfront radiation therapy group was 74 Gy (range, 70-78 Gy relative biological effectiveness), whereas the median total dose in the salvage radiation therapy group was 45 Gy (range, 39-51 Gy relative biological effectiveness). The median duration of LC was 21 months in both the upfront and salvage groups. The overall median LC across all patients was 14 months. The 2-year LC rate was 73% for the upfront radiation therapy group and 52% for the salvage radiation therapy group, with a statistically significant difference ( Conclusions: CIRT-B combined with photon radiation therapy is an effective and safe treatment for advanced NPSC in both primary and salvage settings.

Identifiers

PMID41216205
PMCPMC12596577

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.